Edoxudine hydrate | antiviral drug

MedKoo Cat#: 584382 | Name: Edoxudine hydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Edoxudine is an antiviral agent that has been found to have good efficacy in vivo experiments on hairless mice infected with herpes simplex virus 1.

Chemical Structure

Edoxudine hydrate

CAS#Edoxudine hydrate

Theoretical Analysis

MedKoo Cat#: 584382

Name: Edoxudine hydrate

CAS#: Edoxudine hydrate

Chemical Formula: C11H18N2O6

Exact Mass: 256.1059

Molecular Weight: 274.27

Elemental Analysis: C, 48.17; H, 6.62; N, 10.21; O, 35.00

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

Edoxudine hydrate 15176-29-1

Synonym

Edoxudine; EUdR; Epoxudine; Aedurid; Edoxudine hydrate

IUPAC/Chemical Name

2'-Deoxy-5-ethyluridine hydrate

InChi Key

HUCHTCYDQCXXAB-FZRXOQNUSA-N

InChi Code

InChI=1S/C11H16N2O5.H2O/c1-2-6-4-13(11(17)12-10(6)16)9-3-7(15)8(5-14)18-9;/h4,7-9,14-15H,2-3,5H2,1H3,(H,12,16,17);1H2/t7-,8+,9+;/m0./s1

SMILES Code

OC[C@@H]1[C@H](C[C@H](N2C(NC(C(CC)=C2)=O)=O)O1)O.[H]O[H]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 274.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sacks SL, Tyrrell LD, Lawee D, Schlech W 3rd, Gill MJ, Aoki FY, Martel AY, Singer J. Randomized, double-blind, placebo-controlled, clinic-initiated, Canadian multicenter trial of topical edoxudine 3.0% cream in the treatment of recurrent genital herpes. Canadian Cooperative Study Group. J Infect Dis. 1991 Oct;164(4):665-72. PubMed PMID: 1894930. 2: Kaul R, Hempel B, De Clercq E. [Penetration and action of edoxudine in vitro and in vivo]. Arzneimittelforschung. 1989 Mar;39(3):366-8. German. PubMed PMID: 2757660. 3: Focher F, Lossani A, Verri A, Spadari S, Maioli A, Gambino JJ, Wright GE, Eberle R, Black DH, Medveczky P, Medveczky M, Shugar D. Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34. Epub 2007 Apr 16. PubMed PMID: 17438061; PubMed Central PMCID: PMC1891389. 4: Imperia PS, Lazarus HM, Dunkel EC, Pavan-Langston D, Geary PA, Lass JH. An in vitro study of ophthalmic antiviral agent toxicity on rabbit corneal epithelium. Antiviral Res. 1988 Jul;9(4):263-72. PubMed PMID: 3144240. 5: Chehrehasa F, Ekberg JA, St John JA. A novel method using intranasal delivery of EdU demonstrates that accessory olfactory ensheathing cells respond to injury by proliferation. Neurosci Lett. 2014 Mar 20;563:90-5. doi: 10.1016/j.neulet.2014.01.043. Epub 2014 Jan 31. PubMed PMID: 24486842. 6: Cheraghali AM, Knaus EE, Wiebe LI. Bioavailability and pharmacokinetic parameters for 5-ethyl-2'-deoxyuridine. Antiviral Res. 1994 Dec;25(3-4):259-67. PubMed PMID: 7710272. 7: Kaul R, Kiefer G, Erhardt S, Hempel B. 2-14C-1-(2'-deoxy-beta-D-ribofuranosyl)-5-ethyluracil: synthesis and biotransformation in rats. J Pharm Sci. 1980 May;69(5):531-4. PubMed PMID: 7381737. 8: Lee YW, Giziewicz JB, Knaus EE, Wiebe LI. Tumor uptake of radiolabelled pyrimidine bases and pyrimidine nucleosides in animal models: VII. [2-14C]-5-ethyl-1-(2'-deoxy-beta-D-ribofuranosyl)uracil. Int J Appl Radiat Isot. 1984 Nov;35(11):1063-6. PubMed PMID: 6335492. 9: Kumar R, Wiebe LI, Knaus EE. Synthesis and antiviral activity of 5-ethyl-5-halo-6-alkoxy-(or azido)-5,6-dihydro-2'-deoxyuridine diastereomers as potential prodrugs to 5-ethyl-2'-deoxyuridine. Arch Pharm (Weinheim). 1997 Aug;330(8):259-63. PubMed PMID: 9361522. 10: Cory JG, Halley MC, Jeney A, Lapis K. 5-Hexyl-2'-deoxyuridine blocks the cytotoxic effects of 5-fluorodeoxyuridine or deoxyadenosine in leukemia L1210 cells in culture. Cancer Res. 1990 Aug 1;50(15):4552-6. PubMed PMID: 2142444. 11: Shealy YF, O'Dell CA, Arnett G, Shannon WM. Synthesis and antiviral activity of the carbocyclic analogues of 5-ethyl-2'-deoxyuridine and of 5-ethynyl-2'-deoxyuridine. J Med Chem. 1986 Jan;29(1):79-84. PubMed PMID: 3001308. 12: Kralovánszky J, Katona C, Jeney A, Pandi E, Noordhuis P, Erdélyi-Tóth V, Otvös L, Kovács P, Van der Wilt CL, Peters GJ. 5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil. J Cancer Res Clin Oncol. 1999 Dec;125(12):675-84. PubMed PMID: 10592100. 13: Mucsi I. Combined antiviral effects of flavonoids and 5-ethyl-2'-deoxyuridine on the multiplication of herpesviruses. Acta Virol. 1984 Sep;28(5):395-400. PubMed PMID: 6151353. 14: Joly JM, Williams WM. Elimination of the antiviral drug 5-ethyl-2'-deoxyuridine by the isolated perfused rat liver. Drug Metab Dispos. 1991 Nov-Dec;19(6):1058-65. PubMed PMID: 1687011. 15: Jeney A, Barrie SE, Taylor GA, Newell DR, Harrap KR, Szabolcs A, Lapis K, Otvös L. 5-Ethyl-2'-deoxyuridine: an explanation for its lack of cytotoxic action in vivo. Eur J Cancer Clin Oncol. 1986 May;22(5):557-62. PubMed PMID: 3770027. 16: De Clercq E, Bernaerts R. Specific phosphorylation of 5-ethyl-2'-deoxyuridine by herpes simplex virus-infected cells and incorporation into viral DNA. J Biol Chem. 1987 Nov 5;262(31):14905-11. PubMed PMID: 2822705. 17: Joly JM, Williams WM. High-performance liquid chromatographic analysis of 5-ethylpyrimidines and 5-methylpyrimidines in plasma. J Chromatogr. 1991 Feb 15;563(2):392-9. Erratum in: J Chromatogr 1991 Apr 19;565(1-2):552. PubMed PMID: 1878072. 18: Cheraghali AM, Kumar R, Knaus EE, Wiebe LI. Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice. Drug Metab Dispos. 1995 Feb;23(2):223-6. PubMed PMID: 7736915. 19: Teh CZ, Sacks SL. Susceptibility of recent clinical isolates of herpes simplex virus to 5-ethyl-2'-deoxyuridine: preferential inhibition of herpes simplex virus type 2. Antimicrob Agents Chemother. 1983 May;23(5):637-40. PubMed PMID: 6307130; PubMed Central PMCID: PMC184779. 20: McClain CR, Sim FJ, Goldman SA. Pleiotrophin suppression of receptor protein tyrosine phosphatase-β/ζ maintains the self-renewal competence of fetal human oligodendrocyte progenitor cells. J Neurosci. 2012 Oct 24;32(43):15066-75. doi: 10.1523/JNEUROSCI.1320-12.2012. PubMed PMID: 23100427; PubMed Central PMCID: PMC3700539.